Monjazeb, Arta M. http://orcid.org/0000-0001-5175-8004
Daly, Megan E. http://orcid.org/0000-0001-7308-6149
Luxardi, Guillaume http://orcid.org/0000-0003-3338-0583
Maverakis, Emanual
Merleev, Alexander A.
Marusina, Alina I.
Borowsky, Alexander http://orcid.org/0000-0003-3117-9202
Mirhadi, Amin
Shiao, Stephen L.
Beckett, Laurel
Chen, Shuai http://orcid.org/0000-0002-4016-8217
Eastham, David
Li, Tianhong http://orcid.org/0000-0001-7422-3520
Vick, Logan V.
McGee, Heather M. http://orcid.org/0000-0003-3761-5087
Lara, Frances
Garcia, Leslie
Morris, Leigh Anne
Canter, Robert J. http://orcid.org/0000-0002-3331-5418
Riess, Jonathan W.
Schalper, Kurt A. http://orcid.org/0000-0001-5692-4833
Murphy, William J. http://orcid.org/0000-0002-2793-401X
Kelly, Karen
Funding for this research was provided by:
U.S. Department of Defense (W81XWH-15-2-0063, W81XWH-15-2-0063)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA093373, NIH/NCI R01 CA240751, P30CA093373, R01 CA240751, 4R00CA256526, P30 CA093373)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 2 May 2023
Accepted: 11 August 2023
First Online: 2 September 2023
Competing interests
: A.M.M. – Grants/Contracts: Incyte, Merck, Genentech, BMS, Transgene, EMD Serono, Trisalus. Consulting Fees: Atheneum, First Thought, Opinion Site, Alcimed. Honoraria: ANCO, ACVR. Advisory Board and Stock Options: Multiplex Thera. M.E.D.—Grants/Contracts: Merck, Genentech, EMD Serono. Consulting Fees: Astra Zeneca. Honoraria: Curio, Dava. G.L.—none. E.M.—none. A.A.M.—none. A.I.M.—none. A.B.—none. A.M.—none. S.L.S.— none. L.B.—none. S.C.—none. D.E.—none. T.L.—none. L.V.V.—none. H.M.M.—Consulting fees: RefleXion. F.L.—none. L.G.—none. L.A.M.—none. R.J.C.—Advisory Board: NAKI Therapeutics. J.W.R.—Grants/Contracts: AstraZeneca, Boehringer Ingelheim, Merck, Novartis, Revolution Medicines, Spectrum. K.A.S.—Grants/Contracts: Navigate Biopharma, Tesaro/GSK, Moderna Inc., Takeda, Surface Oncology, Pierre-Fabre Research Institute, Merck, Bristol-Myers Squibb, AstraZeneca, Ribon Therapeutics, Eli Lilly, Boehringer-Ingelheim and Akoya Biosciences. Consulting Fees: Clinica Alemana Santiago, Shattuck Labs, AstraZeneca, EMD Serono, Takeda, Torque/Repertoire Therapeutics, Agenus, Genmab, OnCusp, Parthenon Therapeutics, Bristol-Myers Squibb, Roche, CDR life, Sensei Therapeutics, Molecular Templates and Merck. Honoraria: Takeda, Fluidigm, Merck, Brstil Myers Squibb, PeerView, Forefront collaborative. W.J.M.—Grants/Contracts: Merck. K.K.—Grants/Contracts: Genentech, BMS, Transgene. Advisory Board: Genentech. Other: IASLC. A.M.M., M.E.D., and K.K. received support from Genentech in the form of providing Atezolizumab for this clinical trial. Genentech stand to potentially benefit financially from this report. Genentech played no role in the conceptualization, design, data collection, analysis, decision to publish, or preparation of the paper.